Synairgen PLC
SNG
Company Profile
Business description
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.
Contact
Southampton General Hospital, Tremona Road
Mailpoint 810, Level F, South Block
SouthamptonSO16 6YD
GBRT: +44 2380512800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
30
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
With increased AI spending and hopes of future data center expansion, here’s what we think of Nvidia stock.
stocks
Is this overpriced ASX share too much of a gamble?
We raise our fair value after strong results but shares are pricey.
stocks
ASX players that might thrive under a Trump administration
Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian share market. See our top ASX picks that could do better under a second Trump administration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,531.70 | 51.80 | 0.61% |
| CAC 40 | 7,311.80 | 94.97 | 1.32% |
| DAX 40 | 19,263.70 | 260.59 | 1.37% |
| Dow JONES (US) | 43,750.86 | 207.33 | -0.47% |
| FTSE 100 | 8,071.19 | 40.86 | 0.51% |
| HKSE | 19,508.37 | 72.56 | 0.37% |
| NASDAQ | 19,107.65 | 123.07 | -0.64% |
| Nikkei 225 | 38,865.86 | 330.16 | 0.86% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,949.17 | 36.21 | -0.60% |
| S&P/ASX 200 | 8,279.20 | 55.20 | 0.67% |
| SSE Composite Index | 3,373.95 | 5.89 | -0.17% |